AI Article Synopsis
- T2-FLAIR mismatch sign is considered 100% specific for identifying IDH-mutant 1p/19q non-codeleted gliomas, specifically diffuse astrocytomas, but has been shown to have false positives.
- Recent studies indicate that improper use of this sign, particularly by less experienced neuroradiologists, can lead to incorrect classifications of tumors.
- The essay presents various adult brain tumor cases to highlight the importance of strict criteria for using the T2-FLAIR mismatch sign and to illustrate potential errors in its application.
Article Abstract
T2-FLAIR mismatch sign has been advocated to be 100% specific for IDH-mutant 1p/19q non-codeleted gliomas (diffuse astrocytomas). However, false positives have been reported in recent works. Loose application of the criteria may lead to erroneous classification, especially by non-trained neuroradiologists. In this pictorial essay, we aim to bring attention to the need for strict criteria for the application of T2-FLAIR mismatch sign and to discuss the potential pitfalls in the application of these criteria. For that, a series of adult brain tumour cases are presented to demonstrate how to apply this radiological sign in the clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722227 | PMC |
| http://dx.doi.org/10.1259/bjr.20210825 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigating glioma genetics through perfusion MRI: rCBV and rCBF as predictive biomarkers.
Magn Reson Imaging
December 2024
Department of Radiology and Diagnostic Imaging, Nicolaus Copernicus University, Collegium Medicum, Bydgoszcz, Poland.
Background: Brain tumors exhibit diverse genetic landscapes and hemodynamic properties, influencing diagnosis and treatment outcomes.
Purpose: To explore the relationship between MRI perfusion metrics (rCBV, rCBF), genetic markers, and contrast enhancement patterns in gliomas, aiming to enhance diagnostic accuracy and inform personalized therapeutic strategies. Additionally, other radiological features, such as the T2/FLAIR mismatch sign, are evaluated for their predictive utility in IDH mutations.
Enhancing the diagnostic value of T2-FLAIR mismatch sign in IDH-mutated gliomas: Insights and future directions.
Clin Neurol Neurosurg
January 2025
Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, China. Electronic address:
T2/FLAIR mismatch and diffusion restriction as novel pathophysiological markers in MRI evaluation of central tegmental tract hyperintensity in pediatric patients.
Neuroradiology
November 2024
Department of Pediatric Radiology, Faculty of Medicine, Ankara University, Ankara, Turkey.
Introduction: Central tegmental tract hyperintensity (CTTH) on T2-weighted imaging is an uncommon neuroimaging finding in pediatric patients with unclear clinical significance. CTTH may represent either a physiological or pathological process. This study evaluates the relationship between CTTH and MRI sequences (FLAIR, DWI) to explore its diagnostic value.
View Article and Find Full Text PDFComprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase-mutant lower-grade gliomas.
Ann Clin Transl Neurol
November 2024
Department of Cerebrovascular Disease and Neurosurgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Objective: To differentiate glioma grading and determine isocitrate dehydrogenase (IDH) mutation status, which are crucial for prognosis assessment and treatment planning in glioma patients.
Methods: This retrospective study included patients diagnosed with adult diffuse glioma from 1 January, 2018 to 31 July, 2023 in two independent institutions. It documented and analysed clinical and radiographic features.
Clinicopathological and radiological characteristics of false-positive and false-negative results in T2-FLAIR mismatch sign of IDH-mutated gliomas.
Clin Neurol Neurosurg
November 2024
Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address:
Article Synopsis
- The study investigates how clinicopathological and radiological factors influence false-positive and false-negative results for isocitrate dehydrogenase (IDH) mutations in gliomas, focusing on the T2-FLAIR mismatch sign in MRI.
- Out of 1515 patients with gliomas, the false-positive rate was 3.5% and was influenced by factors like patient age and non-restricted diffusion.
- Conversely, the false-negative rate was significantly higher at 39.7% and correlated with patient age, 1p/19q co-deletion, and telomerase promoter mutation, indicating that while misinterpretations can occur, careful evaluation can minimize errors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!